NuVasive PT Raised to $35.00 at Barclays (NUVA)
Investment analysts at Barclays hoisted their target price on shares of NuVasive (NASDAQ:NUVA) from $32.00 to $35.00 in a note issued to investors on Thursday, Analyst Ratings News reports. The firm currently has an “equal weight” rating on the stock. Barclays’ price objective would indicate a potential downside of 0.17% from the stock’s previous close.
Shares of NuVasive (NASDAQ:NUVA) traded up 0.48% on Thursday, hitting $35.23. 374,191 shares of the company’s stock traded hands. NuVasive has a 52 week low of $16.57 and a 52 week high of $35.38. The stock has a 50-day moving average of $32.69 and a 200-day moving average of $27.43. The company’s market cap is $1.572 billion.
NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up 14.0% on a year-over-year basis. On average, analysts predict that NuVasive will post $1.14 earnings per share for the current fiscal year.
In other NuVasive news, SVP Craig Hunsaker sold 4,275 shares of NuVasive stock on the open market in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $32.10, for a total transaction of $137,227.50. Following the completion of the sale, the senior vice president now directly owns 24,980 shares in the company, valued at approximately $801,858. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of other firms have also recently commented on NUVA. Analysts at Zacks downgraded shares of NuVasive from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, January 2nd. They now have a $35.40 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of NuVasive from $31.00 to $35.00 in a research note to investors on Friday, November 15th. They now have a “sector perform” rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of NuVasive from $35.00 to $40.00 in a research note to investors on Friday, November 15th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company’s stock. NuVasive currently has an average rating of “Hold” and a consensus target price of $29.34.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.